Oxalo Therapeutics creates drugs to treat rare kidney diseases and prevent recurring kidney stones.
Oxalo Therapeutics has raised $1000K in total funding. The most recent round was Grant. The last funding was announced in April 2022.
Oxalo Therapeutics's investors include National Science Foundation, MassChallenge, National Institutes of Health, Polsky Center at the University of Chicago.
Oxalo Therapeutics is headquartered in Chicago, United States.
Oxalo Therapeutics creates drugs to treat rare kidney diseases and prevent recurring kidney stones.
Oxalo Therapeutics is at the Grant stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Oxalo Therapeutics — Funding & Investors." VCBacked, April 15, 2022, https://www.vcbacked.co/company/oxalo-therapeutics. Accessed September 3, 2026.
VCBacked. (2022). Oxalo Therapeutics — Funding & Investors. Retrieved September 3, 2026, from https://www.vcbacked.co/company/oxalo-therapeutics
{{cite web |title=Oxalo Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/oxalo-therapeutics |website=VCBacked |access-date=September 3, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated